dc.contributor.author | Peck, B | |
dc.contributor.author | Bland, P | |
dc.contributor.author | Mavrommati, I | |
dc.contributor.author | Muirhead, G | |
dc.contributor.author | Cottom, H | |
dc.contributor.author | Wai, PT | |
dc.contributor.author | Maguire, SL | |
dc.contributor.author | Barker, HE | |
dc.contributor.author | Morrison, E | |
dc.contributor.author | Kriplani, D | |
dc.contributor.author | Yu, L | |
dc.contributor.author | Gibson, A | |
dc.contributor.author | Falgari, G | |
dc.contributor.author | Brennan, K | |
dc.contributor.author | Farnie, G | |
dc.contributor.author | Buus, R | |
dc.contributor.author | Marlow, R | |
dc.contributor.author | Novo, D | |
dc.contributor.author | Knight, E | |
dc.contributor.author | Guppy, N | |
dc.contributor.author | Kolarevic, D | |
dc.contributor.author | Susnjar, S | |
dc.contributor.author | Milijic, NM | |
dc.contributor.author | Naidoo, K | |
dc.contributor.author | Gazinska, P | |
dc.contributor.author | Roxanis, I | |
dc.contributor.author | Pancholi, S | |
dc.contributor.author | Martin, L-A | |
dc.contributor.author | Holgersen, EM | |
dc.contributor.author | Cheang, MCU | |
dc.contributor.author | Noor, F | |
dc.contributor.author | Postel-Vinay, S | |
dc.contributor.author | Quinn, G | |
dc.contributor.author | McDade, S | |
dc.contributor.author | Krasny, L | |
dc.contributor.author | Huang, P | |
dc.contributor.author | Daley, F | |
dc.contributor.author | Wallberg, F | |
dc.contributor.author | Choudhary, JS | |
dc.contributor.author | Haider, S | |
dc.contributor.author | Tutt, AN | |
dc.contributor.author | Natrajan, R | |
dc.date.accessioned | 2021-04-07T13:46:13Z | |
dc.date.available | 2021-04-07T13:46:13Z | |
dc.date.issued | 2021-02-15 | |
dc.identifier.citation | Cancer research, 2021 | |
dc.identifier.issn | 0008-5472 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4493 | |
dc.identifier.eissn | 1538-7445 | |
dc.identifier.doi | 10.1158/0008-5472.can-20-1822 | |
dc.description.abstract | Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies for this hard-to-treat patient population, yet studies using high-throughput and accurate models to define the functions of driver genes in TNBC to date have been limited. Here, we employed unbiased functional genomics screening of the 200 most frequently mutated genes in breast cancer, using spheroid cultures to model in vivo-like conditions, and identified the histone acetyltransferase CREBBP as a novel tumor suppressor in TNBC. CREBBP protein expression in patient tumor samples was absent in 8% of TNBCs and at a high frequency in other tumors, including squamous lung cancer, where CREBBP-inactivating mutations are common. In TNBC, CREBBP alterations were associated with higher genomic heterogeneity and poorer patient survival and resulted in upregulation and dependency on a FOXM1 proliferative program. Targeting FOXM1-driven proliferation indirectly with clinical CDK4/6 inhibitors (CDK4/6i) selectively impaired growth in spheroids, cell line xenografts, and patient-derived models from multiple tumor types with CREBBP mutations or loss of protein expression. In conclusion, we have identified CREBBP as a novel driver in aggressive TNBC and identified an associated genetic vulnerability in tumor cells with alterations in CREBBP and provide a preclinical rationale for assessing CREBBP alterations as a biomarker of CDK4/6i response in a new patient population. SIGNIFICANCE: This study demonstrates that CREBBP genomic alterations drive aggressive TNBC, lung cancer, and lymphomas and may be selectively treated with clinical CDK4/6 inhibitors. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER ASSOC CANCER RESEARCH | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.title | 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-11-25 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1158/0008-5472.can-20-1822 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2021-01-28 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cancer research | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Genomic Analysis – Clinical Trials | |
icr.researchteam | Functional Genomics | |
icr.researchteam | Molecular and Systems Oncology | |
icr.researchteam | Genomic Analysis – Clinical Trials | |
icr.researchteam | Functional Genomics | |
icr.researchteam | Molecular and Systems Oncology | |
dc.contributor.icrauthor | Buus, Richard | |
dc.contributor.icrauthor | Cheang, Chon | |
dc.contributor.icrauthor | Krasny, Lukas | |
dc.contributor.icrauthor | Huang, Paul | |
dc.contributor.icrauthor | Choudhary, Jyoti | |
dc.contributor.icrauthor | Haider, Syed | |
dc.contributor.icrauthor | Tutt, Andrew | |
dc.contributor.icrauthor | Natrajan, Rachael | |